Advertisement
Advertisement
CLRB
Cellectar Biosciences INC NEW
3.03
USDSponsored
+0.21
+7.52%
Feb 06, 16:00 UTC -5
Closed
After-Market
3.13
+0.10
+3.40%
CLRB Earnings Reports
Positive Surprise Ratio
CLRB beat 19 of 38 last estimates.
50%
Next Report
Date of Next Report
Mar 11, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$2.06
Implied change from Q3 25 (Revenue/ EPS)
--
/+46.10%
Implied change from Q4 24 (Revenue/ EPS)
--
/+14.44%
Cellectar Biosciences INC NEW earnings per share and revenue
On Nov 13, 2025, CLRB reported earnings of -1.41 USD per share (EPS) for Q3 25, beating the estimate of -2.57 USD, resulting in a 45.31% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -18.00% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -2.06 USD, with revenue projected to reach -- USD, implying an increase of 46.10% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Stryker Corporation
Report Date
Jan 29, 2026 For Q4 25
Estimate
$4.43
Actual
$4.47
Surprise
+0.69%
Boston Scientific Corp.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.78
Actual
$0.80
Surprise
+1.61%
ResMed Inc.
Report Date
Jan 29, 2026 For Q2 26
Estimate
$2.75
Actual
$2.81
Surprise
+2.15%
GE HealthCare Technologies Inc. Common Stock
Report Date
Feb 04, 2026 For Q4 25
Estimate
$1.42
Actual
$1.44
Surprise
+0.96%
Envista Holdings Corporation Common stock, $0.01 par value per share
Report Date
Feb 05, 2026 For Q4 25
Estimate
$0.32
Actual
$0.38
Surprise
+15.43%
Prestige Consumer Healthcare Inc.
Report Date
Feb 05, 2026 For Q3 26
Estimate
$1.15
Actual
$1.13
Surprise
-1.36%
Haemonetics Corporation
Report Date
Feb 05, 2026 For Q3 26
Estimate
$1.26
Actual
$1.31
Surprise
+3.75%
Phibro Animal Health Corporation Class A
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.68
Actual
$0.87
Surprise
+27.30%
Canopy Growth Corporation Common Shares
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.04
Actual
-$0.13
Surprise
-198.00%
Aurora Cannabis Inc. Common Shares
Report Date
Feb 04, 2026 For Q3 26
Estimate
$0.21
Actual
$0.12
Surprise
-42.72%
FAQ
What were Cellectar Biosciences INC NEW's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Cellectar Biosciences INC NEW reported EPS of -$1.41, beating estimates by 45.31%, and revenue of $0.00, 0% as expectations.
How did the market react to Cellectar Biosciences INC NEW's Q3 2025 earnings?
The stock price moved down -18%, changed from $3.50 before the earnings release to $2.87 the day after.
When is Cellectar Biosciences INC NEW expected to report next?
The next earning report is scheduled for Mar 11, 2026.
What are the forecasts for Cellectar Biosciences INC NEW's next earnings report?
Based on 6
analysts, Cellectar Biosciences INC NEW is expected to report EPS of -$2.06 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement